SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- ADVENTRX
Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced the
appointment of Brandi L. Roberts to
Chief Financial Officer and Senior Vice President, effective
January 2, 2013. She had served
as the Company's vice president, finance since March 2011.
Ms. Roberts has over 17 years of public accounting and finance
experience, including 14 years at publicly-traded pharmaceutical
and life science companies.
"Brandi's prior experience at publicly-traded, clinical and
commercial stage companies, combined with her business and
financial acumen, enable her to provide important insight and
direction at this important stage for our company," stated
Brian M. Culley, Chief Executive
Officer of ADVENTRX. "With the initiation of our phase 3
trial of ANX‑188 in sickle cell disease and as we solidify plans
for development of ANX-188 in an indication outside of sickle cell
disease, Brandi will continue to be a valuable member of our
management team."
Prior to joining ADVENTRX, from January
2009 to March 2011, Ms.
Roberts served as vice president, accounting and corporate
controller of Alphatec Spine, Inc., the wholly-owned operating
subsidiary of Alphatec Holdings, Inc., a medical technology company
with annual revenue in excess of $170
million listed on the NASDAQ Global Select Market. Ms.
Roberts' experience also includes seven years at Pfizer's
laboratories in La Jolla,
California (formerly Agouron), most recently as director,
finance, and three years with the public accounting firm of
PricewaterhouseCoopers LLP. She is a certified public
accountant with the State of California. Ms. Roberts
currently serves as co-chair of the San Diego Chapter of the
Association of Bioscience Financial Officers.
About ADVENTRX Pharmaceuticals
ADVENTRX
Pharmaceuticals is a biopharmaceutical company developing
proprietary product candidates to treat various diseases and
conditions. The Company's lead product candidate, ANX-188, has
potential to reduce ischemic tissue injury and end-organ damage by
restoring microvascular function, which is compromised in a wide
range of serious and life-threatening diseases and
conditions. The Company initially is developing ANX-188 as a
treatment for complications arising from sickle cell disease. More
information can be found on the Company's web site at
www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions
you that statements included in this press release that are not a
description of historical facts are forward-looking statements that
are based on ADVENTRX's current expectations and assumptions. Such
forward-looking statements include, but are not limited to,
statements regarding the planned phase 3 clinical study of ANX-188,
including the timing of its initiation, and the development of
ANX-188 outside of sickle cell disease. Among the factors
that could cause or contribute to material differences between
ADVENTRX's actual results and those indicated from the
forward-looking statements are risks and uncertainties inherent in
ADVENTRX's business, including, but not limited to: the potential
for delays in the commencement or completion of planned clinical
studies, including the phase 3 study of ANX-188 in sickle cell
disease, including as a result of difficulties in completing
manufacturing process development activities, manufacturing
clinical trial material, meeting applicable regulatory requirements
for clinical trial material, meeting applicable requirements of
institutional review boards overseeing clinical study sites,
negotiating agreements with potential clinical study sites,
enrolling study subjects or being subject to a "clinical hold"; the
risk that the rate of enrollment in the planned phase 3 study of
ANX-188 is slower than was anticipated prior to the study's
initiation; the impact of missing or imputed data on the treatment
effect observed in the prior phase 3 study of ANX-188 in sickle
cell disease; the risk of suspension or termination of a clinical
study, including due to lack of adequate funding or a "clinical
hold"; ADVENTRX's reliance on contract research organizations
(CROs) and other third parties to assist in the conduct of
important aspects of its clinical studies, and that such third
parties may fail to perform as expected; the risk that planned
clinical studies are not successfully executed and/or do not
successfully demonstrate the safety or efficacy of the
investigational drug; the risk that, even if clinical studies are
successful, the FDA determines they are not sufficient to support a
new drug application; the risk that even if clinical studies of an
investigational drug in one indication are successful, clinical
studies of the same investigational drug in another indication may
not be successful; ADVENTRX's ability to obtain additional funding
on a timely basis or on acceptable terms, or at all; the potential
for ADVENTRX to delay, reduce or discontinue current and/or planned
development activities, including clinical studies, partner its
product candidates at inopportune times or pursue less expensive
but higher-risk development paths if it is unable to raise
sufficient additional capital as needed; the risk that the FDA does
not grant marketing approval of ADVENTRX's product candidates,
including ANX-188, on a timely basis, or at all; and other risks
and uncertainties more fully described in ADVENTRX's press releases
and periodic filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange
Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. ADVENTRX
does not intend to revise or update any forward-looking statement
set forth in this press release to reflect events or circumstances
arising after the date hereof, except as may be required by
law.
(Logo:
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a )
SOURCE ADVENTRX Pharmaceuticals, Inc.